Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000363
Filing Date
2025-05-15
Accepted
2025-05-15 14:06:53
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10232
2 ex991.htm EX-99.1 AGREEMENT 3909
  Complete submission text file 0000935836-25-000363.txt   15977
Mailing Address 357 TEHAMA STREET #3 SAN FRANCISCO CA 94103
Business Address 357 TEHAMA STREET #3 SAN FRANCISCO CA 94103 415-448-6534
EcoR1 Capital, LLC (Filed by) CIK: 0001587114 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Subject) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91605 | Film No.: 25951323
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)